Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 2
2008 2
2009 2
2011 4
2012 2
2013 7
2014 9
2015 6
2016 13
2017 7
2018 8
2019 8
2020 12
2021 6
2022 10
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Cadherin-17 as a target for the immunoPET of adenocarcinoma.
Delaney S, Keinänen O, Lam D, Wolfe AL, Hamakubo T, Zeglis BM. Delaney S, et al. Among authors: zeglis bm. Eur J Nucl Med Mol Imaging. 2024 Apr 16. doi: 10.1007/s00259-024-06709-7. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 38625402
MIB Guides: Measuring the Immunoreactivity of Radioimmunoconjugates.
Delaney S, Grimaldi C, Houghton JL, Zeglis BM. Delaney S, et al. Among authors: zeglis bm. Mol Imaging Biol. 2024 Apr;26(2):213-221. doi: 10.1007/s11307-024-01898-x. Epub 2024 Mar 6. Mol Imaging Biol. 2024. PMID: 38446323 Free PMC article.
Evaluating CD133 as a Radiotheranostic Target in Small-Cell Lung Cancer.
Sarrett SM, Rodriguez C, Delaney S, Hosny MM, Sebastiano J, Santos-Coquillat A, Keinänen OM, Carter LM, Lastwika KJ, Lampe PD, Zeglis BM. Sarrett SM, et al. Among authors: zeglis bm. Mol Pharm. 2024 Mar 4;21(3):1402-1413. doi: 10.1021/acs.molpharmaceut.3c01063. Epub 2024 Feb 8. Mol Pharm. 2024. PMID: 38331430 Free PMC article.
First-in-Human Evaluation of Site-Specifically Labeled 89Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
Yeh R, O'Donoghue JA, Jayaprakasam VS, Mauguen A, Min R, Park S, Brockway JP, Bromberg JF, Zhi WI, Robson ME, Sanford R, Modi S, Agnew BJ, Lyashchenko SK, Lewis JS, Ulaner GA, Zeglis BM. Yeh R, et al. Among authors: zeglis bm. J Nucl Med. 2024 Mar 1;65(3):386-393. doi: 10.2967/jnumed.123.266392. J Nucl Med. 2024. PMID: 38272704 Free PMC article.
Click Chemistry and Radiochemistry: An Update.
Bauer D, Cornejo MA, Hoang TT, Lewis JS, Zeglis BM. Bauer D, et al. Among authors: zeglis bm. Bioconjug Chem. 2023 Nov 15;34(11):1925-1950. doi: 10.1021/acs.bioconjchem.3c00286. Epub 2023 Sep 22. Bioconjug Chem. 2023. PMID: 37737084 Free PMC article. Review.
Molecular Imaging, Radiochemistry, and Environmental Pollutants.
Delaney S, Sebastiano J, Zeglis BM, Keinänen OM. Delaney S, et al. Among authors: zeglis bm. J Nucl Med. 2023 Aug;64(8):1179-1184. doi: 10.2967/jnumed.122.265209. Epub 2023 Jul 13. J Nucl Med. 2023. PMID: 37442598 Free PMC article. Review.
Visualizing Galectin-3 Binding Protein Expression with ImmunoPET.
Keinänen O, Sarrett SM, Delaney S, Rodriguez C, Dayts EJ, Capone E, Sauniere F, Ippoliti R, Sala G, Iacobelli S, Zeglis BM. Keinänen O, et al. Among authors: zeglis bm. Mol Pharm. 2023 Jun 5;20(6):3241-3248. doi: 10.1021/acs.molpharmaceut.3c00241. Epub 2023 May 16. Mol Pharm. 2023. PMID: 37191353 Free PMC article.
103 results